{"entity":{"id":"bcb-276","kind":"drug","name":"BCB-276","aka":[],"tldr":"BCB-276 is an experimental CAR-T cell therapy from BrainChild Bio in phase 2 trials for glioma & glioblastoma, aimed at B7-H3.","summary":"BCB-276 is a CAR-T cell therapy developed by BrainChild Bio. Its target is B7-H3 (the sponsor names B7-H3). The sponsor states: An autologous CAR T-cell therapy targeting B7-H3, an antigen described as universally expressed in diffuse intrinsic pontine glioma (DIPG), manufactured from the patient's own leukapheresed immune cells after standard radiation therapy. ClinicalTrials.gov describes the intervention as: Following completion of standard radiation therapy, eligible participants with DIPG will undergo leukapheresis, a procedure to collect white blood cells used to manufacture BCB-276, an autologous CAR T cell therapy made from the participant. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in glioma & glioblastoma. The largest, NCT07680439, plans to enrol 75 participants with primary completion expected 2028-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of BCB-276","url":"https://clinicaltrials.gov/search?intr=BCB-276"},{"label":"Sponsor pipeline page","url":"https://brainchildbio.com/pipeline/"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":["b7h3"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07680439"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"CAR-T cell therapy","mechanism":"An autologous CAR T-cell therapy targeting B7-H3, an antigen described as universally expressed in diffuse intrinsic pontine glioma (DIPG), manufactured from the patient's own leukapheresed immune cells after standard radiation therapy.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bcb-276/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"target":[{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/"}],"trial":[{"id":"nct07680439","kind":"trial","name":"Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).","route":"/trials/nct07680439/"}]}}